Lung Cancer ASCO 2023 Highlights with Dr. Charu Aggarwal

Discussing Lung Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Charu Aggarwal, Director, Precision Oncology Innovation, Associate Professor of Lung Cancer Excellence at Penn Medicine. Covering three important studies:

- ADAURA trial update with increased OS with adjuvant Osimertinib

- KEYNOTE 789 - Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant

- KEYNOTE 671 - Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC